

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) ~~Pharmaceutical~~ A pharmaceutical, cosmetic, dietetic or nutraceutical ~~compositions~~ composition comprising:

a first vasoactive agent;

a second vasoactive agent; and

a third vasoactive agent, wherein,

- the first vasoactive agent is visnadin or
esculoside[[;]],

- the second vasoactive agent comprises at least one compound selected from the group consisting of icarin, [[or]] icarin derivatives, thereof or extracts containing [[it]] icarin, *Ginkgo biloba* dimeric flavones either in [[the]] a free form or complexed with phospholipids, and amentoflavone[[;]], and

- the third vasoactive agent comprises at least one compound selected from the group consisting of escin, escin beta-sitosterol complexed with phospholipids, sericoside, sericoside

complexed with phospholipids ~~[[or]],~~ and *Centella asiatica* extract in ~~[[the]]~~ a free form or complexed with phospholipids.

2. (currently amended) ~~Compositions~~ The composition as claimed in claim 1, wherein,

the first vasoactive agent is 0.05-2% by weight,

the second vasoactive agent is 0.1-1% by weight, and

the third vasoactive agent is 0.5-2% by weight.

~~having the following concentration ranges by weight:~~

~~—Visnadin or esculeside: 0.05-2%;~~

~~—amentoflavone or *Gingko biloba* dimeric flavones in the free form or complexed with phospholipids: 0.1-1%;~~

~~—icarin or derivatives thereof or extracts containing it: 0.1-1%;~~

~~—Escin, escin beta sitosterol complexed with phospholipids, sericoside, sericoside complexed with phospholipids or *Centella asiatica* extract in the free form or complexed with phospholipids: 0.5% 2%.~~

3. (withdrawn/currently amended) ~~Compositions~~ The composition as claimed in claim 1, ~~in which~~ wherein the icarin derivatives are selected from the group consisting of ~~comprise~~ 7-hydroxyethyl-icarin, 7-ethylamino-icarin, 7-aminoethyl-icarin, 7-

hydroxyethyl-3-O-rhamnosyl-icarin, 7-aminoethyl-3-rhamnosyl-icarin, 8-dihydro-icarin and ~~[[its]]~~ glucosides thereof in 7 and 3, and 7-hydroxyethyl-7-desglucoicarin.

4. (currently amended) ~~Compositions~~ The composition as claimed in claim 1, ~~in the form of creams, gel, lotions, milk~~ wherein the composition is in a form selected from the group consisting of a cream, a gel, a lotion, and a milk.

5. (currently amended) ~~[[A]]~~ The composition as claimed in claim 1, wherein the first vasoactive agent is ~~containing~~ Visnadin.

6. (withdrawn/currently amended) ~~[[A]]~~ The composition as claimed in claim 1, ~~containing~~ wherein,

the first vasoactive agent is Visnadin,

the second vasoactive agent comprises 7-hydroxyethyl-7-desgluco-icarin~~[[,]]~~ and amentoflavone, and

the third vasoactive agent comprises escin.

7. (withdrawn/currently amended) ~~[[A]]~~ The composition as claimed in claim 1, wherein,

the first vasoactive agent is ~~containing~~ esculoside,

the second vasoactive agent comprises icarin~~[[,]]~~ and amentoflavone, and

the third vasoactive agent comprises escin.

8. (withdrawn/currently amended) [[A]] The composition
as claimed in claim 1, wherein,

the first vasoactive agent is ~~containing~~ Visnadin,
and

the second vasoactive agent comprises 7-hydroxyethyl-
7-desgluco-icarin[[,]] and *Gingko biloba* dimers in [[the]] a free
form or complexed with phospholipids.

9. (currently amended) [[A]] The composition as claimed
in claim 1, wherein,

the first vasoactive agent is ~~containing~~ Visnadin,
the second vasoactive agent comprises *Gingko biloba*
dimers complexed with phospholipids, and

the third vasoactive agent comprises escin beta-
sitosterol complexed with phospholipids.

10. (withdrawn/currently amended) [[A]] The composition
as claimed in claim 1, wherein,

the first vasoactive agent is ~~containing~~ esculoside,
the second vasoactive agent comprises *Gingko biloba*

dimers complexed with phospholipids, and

the third vasoactive agent comprises escin beta-sitosterol complexed with phospholipids.

11-12. (canceled)